Nintedanib Inhalation for Pulmonary Fibrosis

(INFLO-2 Trial)

This trial tests an inhalable medication called Nintedanib to determine its effectiveness for people with idiopathic pulmonary fibrosis (IPF), a lung disease that scars the lungs and impairs breathing. Researchers aim to assess the safety of this treatment and its potential to improve lung function and reduce breathing issues. Participants will receive either Nintedanib or a placebo (a non-active substance) and will switch to the real treatment after 12 weeks. Ideal candidates have been diagnosed with IPF, are on stable treatment, and experience regular breathing difficulties. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group of people.

The trial does not specify if you need to stop taking your current medications, but it mentions that you should not use prohibited medications during the study. If you are on pirfenidone or nerandomilast, you must be on a stable dose for at least 3 months before joining the trial.

Previous studies have found nintedanib dry powder inhalation to be safe and well tolerated. Participants using this inhaled medicine did not experience severe side effects during the study period. This includes inhalable forms like SD-NTB and NTB-METSD, which effectively treated lung problems such as pulmonary fibrosis. Overall, the inhaled version of nintedanib appears safe based on the data collected so far.¹²³⁴⁵

Researchers are excited about Nintedanib Dry Powder Inhalation for pulmonary fibrosis because it offers a new delivery method that could improve patient convenience and adherence. Unlike current treatments such as oral medications and injections, this treatment is inhalable, allowing the drug to directly target the lungs. This method may potentially reduce systemic side effects and improve the drug's effectiveness. Additionally, Nintedanib is known for its ability to slow disease progression by blocking multiple pathways involved in fibrosis, which is a different mechanism from some existing treatments.

Research has shown that nintedanib, taken as a pill, is already approved for treating idiopathic pulmonary fibrosis (IPF) and can slow its progression. In this trial, participants will receive either the dry powder inhalation (DPI) form of nintedanib or a placebo. Early studies have demonstrated that the DPI form is safe and well tolerated. This inhalable form might cause fewer side effects than the pill version. Preclinical studies suggest that inhaled nintedanib effectively targets the lungs, helping to manage lung fibrosis. While more information is needed, these findings are promising for those considering participation in trials for this inhalable treatment.¹²³⁶⁷